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Abstract
Objectives: Variants of the secreted glycoprotein, proprotein convertase subtilisin/kexin 9 (PCSK9), associate with
both hypo- and hyper-cholesterolemic phenotypes. Herein, we carried out full exonic sequencing of PCSK9
documenting the frequency of single and multiple PCSK9 variations and their effects on serum lipoprotein and
PCSK9 levels in Caucasian Canadians.
Methods: The 12 exons of PCSK9 were sequenced in 207 unrelated Caucasian Canadians. Minor allele frequencies
of PCSK9 variants were compared amongst LDL cholesterol (LDLC) quintiles. Serum PCSK9 levels were measured by
ELISA and lipoproteins by enzymatic methods. Comparisons were made with a Caucasian family cohort (n = 51) and
first generation African Canadians (n = 31).
Results: In Caucasians, but not African Canadians, the c.61_63insCTG (denoted L10Ins) and A53V PCSK9 variations
were linked and their frequency was significantly higher among Caucasian Canadians with LDLC levels in the <25th
percentile. In both the unrelated and family Caucasian cohorts those carrying the L10A53V PCSK9 variant had
significantly lower LDLC without reduction in plasma PCSK9. The I474V PCSK9 variant associated with significantly
lower serum PCSK9 and LDLC. A novel PCSK9 variant was identified; E206K. We found that the frequency of
multiple PCSK9 variations was higher in first generation African Canadians.
Conclusions: We showed that the L10A53V and I474V PCSK9 variants were significantly associated with lower LDLC
levels in Caucasian Canadians but differed in their effect on serum PCSK9 concentrations, illuminating differences in
their mechanism of inaction and indicating that that PCSK9 measurement alone may not always be a good
indicator of PCSK9 function.
Full exonic sequencing of PCSK9 pointed to factors that may contribute to L10Ins PCSK9 variant loss of function in
Canadians of Caucasian but not those of African descent. These included; (1) its tight linkage with the A53V variant
in Caucasians and/or (2) for both the L10 and I474V, the combined (and negating) effect of multiple, differing
phenotypic PCSK9 variants within individuals of African ancestry for which combinations of PCSK9 variations and
their overall frequency was higher. No population studies, to our knowledge, have addressed or accessed the effect
of multiple PCSK9 variants on cholesterol profiles. Our results indicate that this should be considered.
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Background
Elevated low density lipoprotein cholesterol (LDLC) levels
are recognized as a major risk factor for coronary artery
disease [1,2]. Cell surface liver low density lipoprotein re-
ceptors (LDLR) clear LDL particles from circulation by
binding LDL particles through its protein component,
apolipoprotein B100 (ApoB100), followed by endocytosis
[3]. LDL is released from the LDLR in the endosome and
travels to the lysosome for degradation, while the LDLR
recycles to the cell surface. Gene variations in LDLR (low
density lipoprotein receptor) and APOB (apolipoprotein
B100) were identified as causes of autosomal dominant
hypercholesterolemia (ADH) and named familial hyper-
cholesterolemia (FH) 1 and FH2, respectively [2]. They ac-
count for approximately 80% of all FH cases [4,5]. The
FH3 locus was identified in 2003 by Abifadel et al. as
PCSK9 (Proprotein Convertase Subtilisin/kexin type 9) [6].
PCSK9 is the ninth member of a family of endopro-
teolytic enzymes important in development and normal
physiology due to their regulated proteolytic maturation
of proproteins including neuropeptides, hormones, cyto-
kines, growth factors, receptors, cell surface and serum
proteins [7,8]. The 12 exons of PCSK9 encode a 692
amino acid secreted glycoprotein [9]. PCSK9, like its fam-
ily members, is synthesized as a preproprotein containing
several well-defined motifs including a pre-signal, pro-
inhibitory, catalytic and c-terminal domain [10]. Following
autocatalytic cleavage, PCSK9 and its inhibitory pro do-
main are secreted as a heterodimer [9]. Therefore, unlike
its family members, PCSK9 does not function as an en-
zyme and instead plays a ‘moonlighting’ role as an escort
protein [11,12]. PCSK9 binds to LDLR at the cell surface
[13] and escorts it from the endosomal recycling pathway
toward the lysosomal compartment for degradation,
thereby modifying circulating LDLC levels [14-17]. Re-
gions within PCSK9’s catalytic, pro and c-terminal do-
mains have been implicated in the equilibrium between
PCSK9:LDLR binding at the cell surface and in the endo-
some [13,18-21]. PCSK9 variants have been identified in
each of these domains, some of which associate with sig-
nificant changes in circulating LDLC levels; PCSK9 vari-
ants that associate with hypercholesterolemia or ADH
[22-26] are termed ‘gain of function’, while PCSK9 ‘loss of
function’ variants associate with hypocholesterolemia and
reduced risk of coronary artery disease [27-33].
Minor allele frequencies (MAF) of ‘gain of function’
PCSK9 variants that associate with ADH are relatively
low and account for approximately 2.3% of ADH [4,34].
‘Loss of function’ PCSK9 variations that result in very
low cholesterol levels (ie <5th percentile) like the C679X
and Y142X found in African Americans occur with a
combined MAF of 2% in that population [28]. Phenotyp-
ically milder ‘loss’ and ‘gain of function’ PCSK9 variants
are more widespread, and their MAFs and phenotypic
influence can vary with ethnicity [28,31,32,35,36]. For in-
stance, the PCSK9 R46L variant associates with lower
LDLC levels in Caucasian populations at a MAF of 1.6%
but at 0.28% in African Americans [30]. The PCSK9
A443T that associates with lower LDLC levels in African
Americans (MAF 9.4%) is found at 0.048% in Caucasians.
The PCSK9 c.61_63insCTG variant (denoted L10Ins) is
found at similar MAFs (between 11 and 15%) in Caucasians
[32] and Japanese [31], but associates with lower LDLC
levels in Caucasians [32].
We recently observed several common loss of function
PCSK9 variants in a French Canadian cohort (including
L10insA53V, R46L and I474V) in addition to a novel,
strong loss of function PCSK9 Q152H variant [37,38].
This variant precludes proPCSK9 processing and secre-
tion and has a dominant negative effect on wildtype
PCSK9 [37]. In this paper we extend these findings by
determining which PCSK9 variations associated with low
LDLC levels (<25th percentile) in a mixed Caucasian
Canadian population and compared their frequency in
Caucasian Canadians with LDLC in the 25-49th, 50-74th,
75-95th and >95th percentiles (age and gender matched).
We investigated the influence of PCSK9 variants on serum
lipid and PCSK9 levels in this population and in a large
Caucasian family. To begin to study ancestry and PCSK9
variations, we compared our above results with PCSK9
variations found in first generation African Canadians.
Unlike many studies on the influence of PCSK9 variants
on serum lipid levels, genotyping of our subjects is based
on complete exonic sequencing of the PCSK9 gene and
not selective sequencing for a particular variation. This is
an important consideration when studying a polymorphic
gene like PCSK9.
Results
Clinical characteristics of low density lipoprotein
cholesterol (LDLC) quintiles in an unrelated Caucasian
Canadian population
Figure 1 shows scatter plot representation of the mean ±
SD for lipids, serum PCSK9, body mass index (BMI) and
age of LDLC sub-groups; <25th (n = 51), 25-49th (n = 48),
50-74th (n = 45), 75-95th (n = 46) and >95th (n = 17) per-
centiles, adjusted for age and gender. The <25th LDLC
percentile group was compared to other sub-groups and
statistical differences noted (Figure 1). As expected TC
(Panel A) was significantly increased in each LDLC sub-
group in comparison to the <25th LDLC percentile sub-
group. Panel B shows that plasma PCSK9 in the <25th
LDLC percentile sub-group (260.8 ± 103.5 ng/ml) was
significantly lower than the 25-49th (345.2 ± 158 ng/ml,
p < 0.05), 50-74th (330.7 ± 102 ng/ml, p < 0.001) and
75-95th (375.1 ± 117.6 ng/ml, p < 0.0001) LDLC percentile
sub-groups. However, although lower, plasma PCSK9 in
the <25th LDLC percentile sub-group (260.8 ng/ml ±
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103.5) was not significantly different from the >95th LDLC
percentile subgroup (Panel B; at 334.4 ng/ml ± 156).
Triglyceride and HDLC levels did not differ between
LDLC sub-groups, nor did BMI and age (Panels C-F, re-
spectively). Serum PCSK9 was positively correlated with
TC (r = 0.3919, p < 0.0001), LDLC (r = 0.3312, p < 0.0001)
and HDLC (r = 0.2647, p = 0.0001) but not TG, age and
BMI (Additional file 1: Figure S1). Our sample population
is largely Caucasian based on self-reporting but would be
multiethnic in ancestry; 25% British, 22% French, 24%
Irish, 20% other Europeans, 7% Asian and 2% other (Sta-
tistics Canada).
PCSK9 variations in the Caucasian Canadian population
Table 1 shows the PCSK9 exonic variants identified in our
Caucasian Canadians and their percent MAF (%) sub-


































































































































Figure 1 Scatter plot representation of mean ± SD of serum lipid and PCSK9 concentrations as well as age and BMI in a Caucasian
Canadian population by LDL Cholesterol quartile, adjusted for age and gender. Comparisons of the <25th LDLC percentile with other
LDLC subgroups by Kruskal-Wallis Test with Dunn’s Multiple Comparison Post Test. Significance is indicated as *p < 0.05, **p < 0.001, ***p < 0.0001.
Table 1 Comparison of minor allele frequencies (%) for PCSK9 exonic single nucleotide variations in a Caucasian
Canadian population subdivided by LDLC quintiles
LDLC percentile
group
Group < 25th 25-49th 50-74th 75-95th >95th All
(n = 51) (n = 48) (n = 45) (n = 46) (n = 17) (n = 207)
PCSK9 Variant Sub-Group Minor Allele Frequencies (MAF %) All MAF (%)
L10Ins/A53V 20.6 10.4* 10.0* 7.6** 2.9* 15.5
L10Ins/A53V (Homo) NF NF 2.2 1.1 5.9 1.9
L10Ins NF 1.0 NF 1.1 NF 0.24
R46L 2.9 1.0 3.3 1.1 NF 0.24
R93C 0.98 NF NF NF NF 0.24
E206K NF NF NF 1.1 NF 0.24
I474V 15.7 12.5 16.7 7.6 5.9 12.6
I474V(Homo) 2.0 NF 3.3 NF NF 2.4
H553R NF NF NF NF 5.9 0.24
E670G 2.9 4.2 4.4 2.2 5.9 3.6
MAF, minor allele frequency; NF, not found; Fisher’s Exact Test comparing <25thpercentile MAF to each other group *p = 0.033 (25-49th); *p = 0.046 (50-74th);
**p = 0.0067 (75-95th); *p = 0.037 (>95th); Chi-squared 0.016 comparing all groups.
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divided by LDLC quintiles, and in the whole population.
We identified known PCSK9 variants including the R46L
and L10Ins associated with reduced LDLC in Caucasians
[32] and the I474V and E670G not reported to affect
LDLC in Caucasians. Our MAF (%) for these variations
are similar to those previously reported; 1.9 for R46L ver-
sus 1.6 in [30]; 15.5 for L10Ins versus 12.8 in [32]; 12.6 for
I474V versus 18 in [30]; and 3.6 for E670G versus 3.4 in
[39]. In our Caucasian Canadians -and as reported for
European and Japanese populations- the L10ins [within
the signal peptide domain of PCSK9] showed linkage dis-
equilibrium with the A53V variation in the prodomain of
PCSK9 [31,32]. We identified a PCSK9 variant R93C
reported in a Japanese population to associate with low
LDLC [31]. This individual reported distant Asian ances-
try. We found the H553R PCSK9 variant that associates
with increased LDLC [30] in an individual in >95th per-
centile LDLC sub-group and of Latin American ancestry.
One individual carried a novel PCSK9 variant E206K
(95th percentile for LDLC). Table 2 shows the frequency
of single and multiple PCSK9 exonic variants in the
Caucasian cohort. 101 of our 207 Caucasian participants
(48.7%) did not carry any exonic PCSK9 variant. 71 or
34.3% carried one PCSK9 variant. 35 of our 207 Caucasian
participants (16.9%) carried two or more PCSK9 exonic
variants. The effect of PCSK9 variants on lipoprotein pa-
rameters has been reported in several populations, but to
our knowledge no study has addressed how the presence
of multiple PCSK9 variants affects our understanding of
the loss- and gain- of function of PCSK9 variation in lar-
ger population studies. In our population we cannot say
whether these multiple variations occur on the same or
separate alleles.
PCSK9 variations in the African Canadian population
We compared the findings in our Caucasian group to 31
individuals who self-identified as first generation African
Canadians. Table 3 shows the PCSK9 variants identified,
their MAFs and previously reported effect on LDLC
levels in those of African ancestry. One carried the
Table 2 Frequency of single and multiple PCSK9 exonic variations in Caucasian and African Canadian populations
PCSK9 Variant PCSK9 Variant
Combined frequency (%) in Canadian population Combined frequency (%) in African population
No PCSK9 Exonic Variations (n = 101) 48.7% No PCSK9 Exonic Variations (n = 6) 19.4%
Carriers of Single PCSK9 Exonic Variations (n = 71) 34.3% Carriers of single PCSK9 ExonicVariations (n = 8) 25.8%
L10Ins/A53V (n = 26) L10Ins (n = 3)
L10Ins (n = 1) A443T (n = 1)
R46L (n = 1) I474V (n = 2)
I474V (n = 33) H417Q (n = 1)
R93C (n = 1) H553R (n = 1)
E670G (n = 9) E670G (n = 1)
Carriers of Multiple PCSK9 Exonic Variations (n = 35) 16.9% Carriers of Multiple PCSK9 ExonicVariations (n = 17) 54.8%
L10Ins/A53V -L10Ins/A53V (n = 3) L10Ins/R469W (n = 1)
L10Ins/A53V -L10Ins/A53V –I474V (n = 1) L10Ins/I474V/H553R (n = 1)
L10Ins/A53V -I474V (n = 13) L10Ins/I474V/E670G (n = 2)
L10Ins/A53V -E206K -I474V (n = 1) L10Ins/N425S/I474V (n = 2)
L10Ins/A53V -I474V -I474V (n = 1) L10Ins/R469W/E670G (n = 1)
L10Ins/A53V -R46L (n = 4) L10Ins/E670G(Homo) (n = 1)
L10Ins/A53V -R46L -I474V (n = 2) L10Ins(Homo)/I474V (n = 1)
L10Ins/A53V -E670G (n = 1) L10Ins(Homo)/E670G (n = 1)
L10-E670G (n = 1) L10Ins/A443T/I474V/E670G (n = 1)
R46L -I474V (n = 1) L10Ins/A443T(Homo)/H553R/Q619P (n = 1)
R46L -E670G (n = 1) L10Ins(Homo)/I474V/E670G(Homo) (n = 1)
I474V -I474V (n = 4) A443T/I474V (n = 1)
I474V -E670G (n = 2) A443T/C679X (n = 1)
I474V/E670G (n = 1)
E670G(Homo) (n = 1)
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H417Q and two the R469W PCSK9 variations associated
with increased LDLC levels in African Americans [30].
Four carried the A443T PCSK9 variant and one of these
the C679X variant associated with reduced LDLC in
African Americans [28,30]. The E670G and I474V are
common polymorphisms in this population with MAFs
of 21 and 19.4%, respectively. This is similar to their
reported frequency in African Americans [30] and, for
the E670G, this variant is significantly more frequent in
our African than Caucasian Canadian cohorts (p <
0.0001). The L10Ins was a common variant in our
African Canadian population - 13 individuals were het-
erozygous and 3 were homozygous for the L10Ins. The
combined MAF in this group for the L10Ins is 30.7%.
Notably, none carried the A53V PCSK9 variant (and −64
C > T variation from ATG) that is linked in the Caucasian
population. The frequency of heterozygosity and homozy-
gosity for the L10Ins in the African Canadian population
(41.9% and 9.7%, respectively) was higher than the
Caucasian Canadian population (22.7% and 1.9%, respect-
ively; p = 0.0044). The frequency of the I474V variant did
not vary between our African and Caucasian cohorts.
Table 2 shows the frequency of single and multiple
PCSK9 exonic variants in our African Canadian popula-
tion. Six of 31 individuals, or 19.4%, did not carry exonic
variations in PCSK9, while 25.8% carried a single PCSK9
variation and a striking 54.8% carried multiple PCSK9
variations. Statistically significant differences were ob-
served in the African and Caucasian Canadian popula-
tions when comparing the frequency of multiple PCSK9
variants (p < 0.0001).
Influence of PCSK9 variations on lipoproteins in the
Caucasian Canadian population
When compared to the other LDLC percentile groups, the
frequency of the L10InsA53V variant was significantly as-
sociated with the <25th percentile (Table 1: Fisher’s Exact
Test comparing <25th percentile MAF to each other group
*p = 0.033 (49-25th); *p = 0.046 (74-50th); **p = 0.0067 (95-
75th); *p = 0.037(>95th); Chi-squared *p = 0.016 comparing
all groups). The frequency of PCSK9 variants R46L, I474V
and E670G were not associated with any LDLC sub-group
(Table 1). The one individual who carried the R93C variant
was in the <25th LDLC percentile, a variant associated
with low LDLC levels in a Japanese population [31]. The
novel variant E206K was identified in a single individual
with LDLC at the 95th percentile. On-going family and cell
biology studies will conclude whether it exerts a gain of
function in PCSK9.
The occurrence of single and multiple PCSK9 variants
in the Caucasian population (Table 2) prompted us to
analyze the effect of our most common PCSK9 variants
(termed ‘carriers’ but not exclusively of that variant) on
lipoprotein parameters in comparison to those that do
not carry that PCSK9 variation (but may carry others
and termed ‘non- carriers’ of said variation (Table 4).
Then to exclude the influence of multiple PCSK9 vari-
ants on a particular PCSK9 variant and its effect on lipo-
protein parameters, we carried out the more vigorous
comparison of individuals who carry a single variation in
PCSK9 (termed ‘X’ variant) with those who carry no
variation in PCSK9 (termed no variant; Table 5). In
Table 4, only the L10A53V PCSK9 carriers show
Table 3 Minor allele frequencies (%) of PCSK9 exonic variations found in African Canadians
PCSK9 Variant MAF n = 31 Reported MAF (%) in African
Americansb
Reported effect on LDLC levels in African
Americansb




H417Q 1.6 0.3b ↑ 10%




N425S 3.2 1.9 nd
I474V 19.4 22b ns
R469W 3.2 0.75b nd
H553R 4.8 1.3 ↑ 10%
E670G 11.3 or 21.0
combined




C679X 1.6 0.72b ↓ 40%
aThe L10Ins was NOT linked to the A53V variation and –64C/T intronicvariation from ATG as seen in Canadian Caucasian Population. bMAF, minor allele frequency
reported by Kotowskiet al 2006. ns: not significant; nd: not determined.
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significantly lower TC (9.5%; p = 0.0047) and LDLC
(16.1%; p < 0.0002) concentrations when compared to
non-carriers. However, the more vigorous comparison of
only a single PCSK9 variant versus no variant (Table 5)
shows not only that the L10A53V PCSK9 carriers show
significantly lower TC (12.5%; p = 0.0032) and LDLC
(19.8%; p = 0.0005) but those that carry exclusively the
I474V have significantly lower LDLC (9.9%; p = 0.05)
and those carrying only the E670G variant have
significantly lower TC (16.2%; p = 0.043) and TG
(27.7%; p = 0.039) levels.
Influence of PCSK9 variations on serum PCSK9
To date, the effect of most PCSK9 variants on serum
PCSK9 concentrations has not been reported. In 2009,
Humphries and colleagues reported that the R46L and
D374Y PCSK9 variants both exhibit lower serum PCSK9
concentrations despite having opposite effects on LDLC





















5.67 ± 1.16 1.54 ± 0.73 1.19 ± 0.35 3.78 ± 1.00 327.2 ± 130.6
L10A53V 0.0047 0.56 0.63 0.0002 0.76
Carrier
(n = 52)
5.13 ± 0.99 1.66 ± 0.82 1.21 ± 0.49 3.17 ± 0.92 326.5 ± 133.0
Non-Carrier
(n = 150)
5.59 ± 1.19 1.54 ± 0.75 1.19 ± 0.37 3.70 ± 1.06 338.6 ±
136.2
I474V 0.13 0.57 0.86 0.056 0.033
Carrier
(n = 57)




5.56 ± 1.14 1.59 ± 0.77 1.20 ± 0.40 3.64 ± 1.01 328.1 ± 127.0
E670G 0.19 0.13 0.36 0.59 0.44
Non-Carrier
(n = 15)
5.11 ± 1.12 1.27 ± 0.48 1.10 ± 0.30 3.45 ± 1.11 313.8 ± 177.9
Variant values represent mean ± SD. Differences between groups were determined by Mann Whitney test with level of significance as p < 0.05.
Table 5 Comparison of serum lipid and PCSK9 concentrations in non-carriers of any PCSK9 variant versus carriers of




















5.82 ± 1.15 1.55 ± 0.72 1.19 ± 0.34 3.93 ± 0.97 341.0 ± 128.9
L10A53V 0.0032 0.82 0.64 0.0005 0.84
Only
(n = 29)
5.09 ± 0.96 1.67 ± 0.86 1.18 ± 0.41 3.15 ± 0.96 352.7 ± 138.5
No Variant
(n = 101)
5.82 ± 1.15 1.55 ± 0.72 1.19 ± 0.34 3.93 ± 0.97 341.0 ± 128.9
I474V 0.097 0.53 0.86 0.050 0.087
Only
(n = 37)
5.48 ± 1.01 1.67 ± 0.81 1.18 ± 0.39 3.54 ± 0.90 301.3 ± 110.2
No Variant
(n = 101)
5.82 ± 1.15 1.55 ± 0.72 1.19 ± 0.34 3.93 ± 0.97 341.0 ± 128.9
E670G 0.043 0.039 0.69 0.14 0.34
Only (n = 9) 4.88 ± 1.01 1.12 ± 0.41 1.14 ± 0.37 3.24 ± 1.08 329.3 ± 227.8
Variant values represent mean ± SD. Differences between groups were determined by Mann Whitney test with level of significance as p < 0.05.
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levels [40]. Herein, we examined the influence of fre-
quent PCSK9 variants found in our Canadian Caucasian
population on serum PCSK9 levels. Table 4 shows that
although the presence of the L10InsA53V variant does
not affect circulating PCSK9 levels (326.5 ± 133.0 (car-
rier) vs 327.2 ± 130.6 ng/ml (non-carrier), carriers do
have significantly lower LDLC concentrations (16.1%;
p = 0.0002). This significance remained when comparing
individuals carrying only the L10InsA53V variant versus
those with no PCSK9 variation. In this instance, serum
PCSK9 again remained unchanged (p = 0.84) while LDLC
were significantly lower by 19.8% (p = 0.0005; Table 5).
Table 5 shows that while the presence of the I474V vari-
ation lowered serum PCSK9 levels by 11.6%, but not sig-
nificantly so (p = 0.087), these carriers have significantly
lower LDLC levels (9.9%; 3.54 ± 0.90 (I474V only) vs
3.93 ± 0.97 mmol/l (no variant) p = 0.050). Interestingly,
carriers with only the E670G variant showed a non-
significant difference in serum PCSK9 but significantly
lower TG concentrations (27.7%; p = 0.039) not seen for
either the L10A53V nor I474V carriers (Table 5).
Influence of PCSK9 variations on lipoprotein parameters
and plasma PCSK9 in a Caucasian family of French
ancestry
To assess whether the results seen in the general Caucasian
population also applied to a family, we measured the lipo-
proteins, plasma PCSK9 and sequenced the 12 exons of
PCSK9 in a French Caucasian pedigree of 51. Nineteen of
the 51 participants (37.3%) carried the L10A53V PCSK9
variant. Three carried the phenotypic strong loss of func-
tion Q152H PCSK9 variant that we characterized in Mayne
et al. (2011), which was associated with 79% lower plasma
PCSK9 and 48% lower LDLC. The comparisons of plasma
lipoproteins and PCSK9 of L10A53V carriers (+L10A53V)
in comparison to non-carriers (−L10A53V) are shown in
Figure 2. Similar to comparisons of the L10A53V variants
in the unrelated Caucasian population, within this pedigree
those that carried the L10A53V variant had significantly
lower LDLC than those that did not carry this PCSK9 vari-
ant (16.9%, p = 0.03: 2.46 ± 0.15 vs 2.96 ± 0.16 ng/ml, re-
spectively). No other lipoprotein parameter, nor age or
BMI differed by L10A53V status in this pedigree. Again
this reduction in LDLC was not due to reduced plasma
PCSK9; L10A53V carriers had 286.0 ± 26.6 ng/ml and non-
carriers 289.1 ± 19.4 ng/ml PCSK9.
Discussion
There are several major findings from this study that com-
pared PCSK9 variations in Caucasian with first generation
African Canadians. The first finding is co-segregation of
the signal peptide c.61_63insCTG variation (L10Ins) with
the prodomain A53V PCSK9 variation in Caucasian but
not African Canadians. Other groups have reported the
tight linkage of the L10Ins and A53V PCSK9 variations as
we have observed here [31,32]. In Yue et al. (2006),









































































































Figure 2 Scatter plot representation of mean ± SD of serum lipid and PCSK9 concentrations as well as age and BMI in a French
Canadian pedigree. –L10A53V and +L10A53V represents non-carriers and carriers of that PCSK9 variant, respectively. Panel A; shows the levels of
plasma PCSK9 and panels B-E lipids (B; LDL cholesterol, C; Total Cholesterol, D; Triglyceride and E; HDL cholesterol) for these two groups.
Differences between groups were determined by Mann Whitney test with level of significance as p < 0.05.
Mayne et al. Lipids in Health and Disease 2013, 12:70 Page 7 of 11
http://www.lipidworld.com/content/12/1/70
the PCSK9 L10Ins variant also associated with lower
LDLC levels [32]. An intronic -64C/T from ATG also
co-segregated with the L10InsA53V variants in our
Caucasian population and as seen previously in other
populations [31,32]. This intronic PCSK9 variation
was not seen in our African cohort. Hence, we report
that the combination of these variations, the intronic -
64C/T from ATG, the L10Ins and A53V are unique to
our Caucasian and not African Canadian populations.
The second finding was that the frequency of the
L10InsA53V variant in our Canadian population was
significantly higher in our low LDLC group (<25th per-
centile) versus those with LDLC levels >25th percentile,
age and gender matched (p = 0.016). This was not ob-
served in African Canadians nor is this variation
reported to affect LDLC levels in African Americans
[30]. We propose that the tight linkage of the L10Ins
with the prodomain A53V variant (and the intronic pro-
moter -64C/T variation) may contribute to the reported
association of the L10Ins with low LDLC in the Cauca-
sian population but not in African Americans.
Thirdly, no study to our knowledge has reported the
frequency of single and multiple PCSK9 variation fre-
quencies in their populations. This is an important con-
sideration since the PCSK9 gene is highly polymorphic
with more than 50 exonic variations documented with
opposing effects on LDLC levels [34]. Herein, we show
that multiple PCSK9 variations are present in both
Caucasian and African populations but are significantly
more frequent in Canadians of African descent. Whereas
48.7% of Caucasian Canadians did not carry any exonic
variation in PCSK9, only 19.4% of our first generation
African Canadians did not carry any exonic variation in
PCSK9 (Table 2). 34.3% of our Caucasian population
and 25.8% of our African population carried single
PCSK9 variations. Striking was the difference in the oc-
currence of multiple PCSK9 exonic variations in our
African population (54.8%) in comparison to 16.9% in
Caucasians. This data prompted us to re-evaluate the
effect of our most common PCSK9 variants in our
Caucasian population (1) in the presence of other vari-
ants and (2) in the absence of multiple variants (Tables 4
and 5, respectively). In the presence of multiple PCSK9
variants only the L10InsA53V carriers showed signifi-
cantly lower TC and LDLC levels (Table 2; 9.5%,
p = 0.0047 and 16.1%, p = 0.0002, respectively). However,
once we evaluated only those single variants against
those that carried no exonic variant in PCSK9 (Table 5)
those that carried the L10InsA53V variations showed a
larger significant decrease of 19.8% LDLC (p = 0.0005)
and those that carried the I474V variation a significant
9.9% decrease in LDLC (p = 0.050). Interestingly, when
we compared the carriers of only E670G variants with
those that carry no PCSK9 exonic variation, although
LDLC levels were non-significantly decreased, their TG
levels were 27.7% lower (p = 0.039). The positive correl-
ation of plasma PCSK9 with TG has been reported in
several population studies yet not others [41,42]. This
difference may be attributable to the occurrence of the
E670G, and indeed other variants in that population that
may affect the degree of correlation to several lipopro-
tein parameters. For instance, in our Caucasian popu-
lation, serum PCSK9 is positively correlated to LDLC
(r = 0.3312, p < 0.0001); however when we measure the
correlation of those carrying only the L10InsA53V var-
iants, this correlation is lost (r = 0.2360, p = 0.2178).
This may not be surprising in light of our fourth finding
that the measurement of plasma PCSK9 illuminates a dif-
ference in the mechanism of action of the L10A53V vari-
ation versus the I474V variation in lowering LDLC in our
Caucasian population. We, and others, have shown that if
plasma PCSK9 levels decrease it is often associated with
decreased LDLC. This is true of the two African missense
mutations, C679X and Y142X, the Caucasian Q152H vari-
ant and the R46L variant [28,37,40]. Circulating PCSK9
levels for carriers of the PCSK9 I474V variant were lower
(11.6%) than the non-variant PCSK9 population, but not
significantly so (p = 0.087). However, this decrease could
contribute to the significantly lower LDLC in these indi-
viduals (9.9%, p = 0.050). In contrast, the L10A53V carriers
did not exhibit any difference in circulating PCSK9 con-
centrations despite a 19.8% reduction in comparison to
persons who do not carry any variation in PCSK9
(p = 0.0005). Again, this points to a different mechanism
of inaction for the loss of function PCSK9 L10A53V
variant.
Conclusions
In conclusion, this study highlights differences in PCSK9
variants found and their frequencies among Caucasian
and African Canadians, and is the first to report on the
frequency of multiple PCSK9 variants. The frequency
was significantly greater in African Canadians probably
reflecting selective historical environmental pressures on
this group. Given these findings further investigation to
catalog specific combinations of PCSK9 variants in vari-
ous populations and large scale studies will be required
to evaluate the effect of multiple variants on PCSK9 bio-
synthesis, secretion and action toward the LDLR and
their combined effect on circulating cholesterol levels
and profiles, as opposed to studies of single variants.
Materials and methods
Population study participants
With informed written consent, blood samples and clin-
ical measurements were obtained for subjects using
Ottawa Hospital Research Institute (OHRI) and Clinical
Research Institute of Montreal (IRCM) ethics committee
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approved study protocols. No participants were on any
lipid-lowering medications. We obtained blood samples
from 238 participants (128 men and 110 women; 207
self-reporting as Caucasian and 31 self-reporting as
African Canadian) recruited by the Ottawa Hospital
Lipid Clinic and 51 participants (25 men and 26 women;
Caucasian family of French Ancestry) recruited from the
IRCM following a 12 hr fast. 207 unrelated individuals
self-reporting as Caucasian were grouped with LDLC
levels in the <25th (n = 51), 25-49th (n = 48), 50-74th
(n = 45), 75-95th (n = 46) and >95th (n = 17) LDLC per-
centile, age and gender matched, as provided in the Lipid
Research Clinics Table [43]. Individuals underwent an-
thropometric measurements including height and weight.
Body mass index (BMI) was calculated according to the
formula: BMI =weight (kg)/height (m)2.
Measurement of serum lipids and lipoproteins
Blood was collected into EDTA-vacuutainer tubes and
centrifuged at 1560 × g for 10 min at 22°C to obtain
plasma and blood leukocytes. To obtain serum for lipid
measurements, blood was collected into SST-vacuutainer
tubes, allowed to clot at room temperature for 20 min and
centrifuged at 1560 × g for 10 min at 22°C. Total choles-
terol (TC) and triglycerides (TG) were measured using en-
zymatic methods on an Ortho Clinical Diagnostics Vitros
250. High density lipoprotein cholesterol (HDLC) was
measured using a direct enzymatic method (Beckman
Coulter) on the Synchron LX20PRO analyzer (Beckman
Coulter) and LDLC was calculated by the Friedewald
equation.
Genotyping
Genomic DNA was isolated from blood leukocytes using
QIAamp DNA Blood Kit (Qiagen Sciences, MD). Primer
sequences and polymerase chain reaction (PCR) for
amplification of the individual exons of the PCSK9 gene
were as per Abifadel et al. (2003). Standard DNA-
sequencing reactions were carried out as a service by
BioBasic Sequencing (Markham, On, CAN).
Measurement of serum PCSK9
The serum PCSK9 assay was carried out using a human
PCSK9 ELISA from CyClex Co (Japan). All samples were
quantified 4× with an intra-assay coefficient of variability
(CV) of 1.5-2.6% and an interassay CV of 2.9-7.1%.
Statistical analyses
Results are expressed as means ± SD except where indi-
cated. Spearman correlation coefficients (r) were deter-
mined to assess the relationship between different
parameters. The unpaired Student t-test, Mann Whitney
test or Kruskal Walis test (with Dunn’s multiple com-
parison post test) was used for statistical analyses of
differences as appropriate and indicated. Minor allele
frequencies were compared using Fisher’s Exact and
Chi-squared tests. Data were analysed using Graphpad
Prism 5 software (La Jolla, CA) and significance defined
as p < 0.05.
Additional file
Additional file 1: Figure S1. The relationship between serum PCSK9
and lipoprotein parameters, age and body mass index (BMI) by
Spearmen correlation (r) and significance (p) using GraphPad Prism 5
Software.
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